Metabolic switching of BILR 355 in the presence of ritonavir. II. Uncovering novel contributions by gut bacteria and aldehyde oxidase

Drug Metabolism and Disposition

Volumn 40, Issue 6, 2012, Pages 1130-1137

  Li, Yongmei ^a   Xu, Jun ^a,b   Lai, W George ^a   Whitcher Johnstone, Andrea ^a   Tweedie, Donald J ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b EISAI RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 ETHYL 5,11 DIHYDRO 5 METHYL 8 [2 [(1 OXIDO 4 QUINOLINYL)OXY]ETHYL] 6H DIPYRIDO[3,2 B:2',3' E][1,4]DIAZEPIN 6 ONE; ALDEHYDE OXIDASE; BILR 355; BILR 402; BILR 516; CYTOCHROME P450 3A4; DRUG METABOLITE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG OXIDATION; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INTESTINE FLORA; MALE; MAXIMUM PLASMA CONCENTRATION; MICHAELIS CONSTANT; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STEADY STATE;

ALDEHYDE OXIDASE; AZEPINES; BACTERIA; DRUG INTERACTIONS; FECES; GASTROINTESTINAL TRACT; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; MICROSOMES, LIVER; PYRIDINES; RITONAVIR; RNA-DIRECTED DNA POLYMERASE;

ANIMALIA; BACTERIA (MICROORGANISMS); HUMAN ECHOVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84862078687     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.044362     Document Type: Article

References (28)

1. Beedham C, Bruce SE, Critchley DJ, al-Tayib Y, and Rance DJ (1987) Species variation in hepatic aldehyde oxidase activity. Eur J Drug Metab Pharmacokinet 12:307-310. (Pubitemid 18058717)
2. Beedham C, Miceli JJ, and Obach RS (2003) Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 23:229-232. (Pubitemid 36807789)
3. Beedham C, Peet CF, Panoutsopoulos GI, Carter H, and Smith JA (1995) Role of aldehyde oxidase in biogenic amine metabolism. Prog Brain Res 106:345-353. (Pubitemid 26027011)
4. Bonneau P, Robinson PA, Duan J, Doyon L, Simoneau B, Yoakim C, Garneau M, Bos M, Cordingley M, Brenner B, Spira B, Wainberg M, Huang F, Drda K, Ballow C, Koenen-Bergmann M, and Mayers D (2005) Antiviral characterization and human experience with BILR 355 BS, a novel next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with a broad anti HIV-1 profile. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston, MA. Poster 558.
5. Boone LR (2006) Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs 7:128-135.
6. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
7. de Béthune MP (2010) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res 85:75-90.
8. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, and Ball SE (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23-29. (Pubitemid 32041675)
9. Guengerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611-650.
10. Houston JB and Galetin A (2008) Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 9:940-951.
11. Huang F, Drda K, MacGregor TR, Scherer J, Rowland L, Nguyen T, Ballow C, Castles M, and Robinson P (2009) Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir. Antimicrob Agents Chemother 53:95-103.
12. Huang F, Koenen-Bergmann M, Macgregor TR, Ring A, Hattox S, and Robinson P (2008) Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 52:4300-4307.
13. Hull MW and Montaner JS (2011) Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med 43:375-388.
14. Kitamura S, Ohashi KNK, Sugihara K, Hosokawa R, Akagawa Y, and Ohta S (2001) Extremely high drug-reductase activity based on aldehyde oxidase in monkey liver. Biol Pharm Bull 24:856-859. (Pubitemid 32633500)
15. Kitamura S, Sugihara K, and Ohta S (2006) Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83-98.
16. Kitamura S and Tatsumi K (1984a) Involvement of liver aldehyde oxidase in the reduction of nicotinamide N-oxide. Biochem Biophys Res Commun 120:602-606.
17. Kitamura S and Tatsumi K (1984b) Reduction of tertiary amine N-oxides by liver preparations: function of aldehyde oxidase as a major N-oxide reductase. Biochem Biophys Res Commun 121:749-754. (Pubitemid 14082243)
18. Klimas N, Koneru AO, and Fletcher MA (2008) Overview of HIV. Psychosom Med 70:523-530.
19. Ley RE, Peterson DA, and Gordon JI (2006) Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124:837-848. (Pubitemid 43261456)
20. Li Y, Lai WG, Whitcher-Johnstone A, Busacca CA, Eriksson MC, Lorenz JC, and Tweedie DJ (2012) Metabolic switching of BILR 355 in the presence of ritonavir. I. Identifying an unexpected disproportionate human metabolite. Drug Metab Dispos 40:1122-1129.
21. Pang KS and Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653. (Pubitemid 8253670)
22. Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, and Tran TD (2010) Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441-8460.
23. Rochat B, Kosel M, Boss G, Testa B, Gillet M, and Baumann P (1998) Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver. Biochem Pharmacol 56:15-23. (Pubitemid 28477447)
24. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
25. Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, and Basit AW (2008) The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 363:1-25.
26. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304:321-333.
27. Tracy TS (2006) Atypical cytochrome P450 kinetics: implications for drug discovery. Drugs R D 7:349-363.
28. Zientek M, Jiang Y, Youdim K, and Obach RS (2010) In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 38:1322-1327.